期刊文献+

42例合并免疫病的深静脉血栓的特点及诊治体会 被引量:3

Features,diagnosis and treatment of deep venous thrombosis with autoimmunity diseases in 42 cases
下载PDF
导出
摘要 目的探讨伴有自身免疫性疾病的深静脉血栓形成的特点及诊断与治疗。方法回顾性分析42例合并免疫性疾病的深静脉血栓形成的特点及诊断、治疗方法。结果42例患者中有15例合并肺栓塞,占35.7%,其中抗磷脂抗体阳性者7例。全部病例经溶栓、抗凝等治疗后都康复出院,随访期间血沉及C-反应蛋白仍高于正常者16例,其中,复发下肢静脉血栓2例,动脉血栓1例,肠系膜上静脉血栓形成1例。结论自身免疫性疾病并发深静脉血栓形成起病隐匿,易被忽视,应早期诊断。抗磷脂抗体综合征是肺栓塞的高危因素,故抗凝周期应延长;并重视原发疾病的治疗。 Objective To explore the features, diagnosis and treatment of deep venous thrombosis with autoimmunity diseases. Methods The features, diagnosis, treatment and effects of 42 patients with autoimmunity diseases were analyzed retrospectively. Results There were 15 patients (35.7 % ) with pulmonary embolism, in which 7 patients were antiphospholipid antibodies positive. All patients were cured and left hospital alive after treated with thrombolytic and anticoagulant. Erythrocyte "sedimentation rate(ESR) and C-reactive protein(CRP) were higher than normal in 16 patients during follow- up, in these 16 patients, 2 of them recurrented deep venous thrombosis, artery thrombosis octcurred in 1 patient, superior mesenteric venous thrombosis was found in 1 patient during follow - up. Conclusion Patients with autoimmunity diseases and deep venous thrombosis are neglected easily in early period and should be diagnosed earlier, antiphospholipid antibodies positive is a risk factor of pul- monary embolism and extended antithrombotic therapy is needed. The treatment of primary diseases is important.
出处 《临床外科杂志》 2006年第3期157-159,共3页 Journal of Clinical Surgery
关键词 自身免疫性疾病 深静脉血栓 诊断 治疗 autoimmunity diseases deep venous thrombosis diagnosis treatment
  • 相关文献

参考文献9

  • 1Nordstrom M,Lindblad B,Bergqvist D,et al.A prospective study of the incidence of deep-vein thrombosis within a defined urban population[J].J Intern Med,1992,232(2):155-160.
  • 2严小枫,涂亚庭.系统性红斑狼疮血栓形成倾向相关机制的研究进展[J].中华风湿病学杂志,2005,9(9):559-561. 被引量:8
  • 3Levy DM,Massicotte MP,Harvey E,et al.Thromboembolism in paediatric lupus patients[J].Lupus,2003,12(10):741-746.
  • 4Love PE,Santoro SA.Antiphospholipid antibodies:anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders.Prevalence and clinical significance[J].Ann Intern Med,1990,112(9):682-698.
  • 5Hyers TM,Agnelli G,Hull RD,et al.Antithrombotic therapy for venous thromboembolic disease[J].Chest,2001,119(Suppl):S176-S193.
  • 6Agnelli G,Prandoni P,Santamaria MG,et al.Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis[J].N Engl J Med,2001,345(3):165-169.
  • 7Pinede L,Ninet J,Duhaut P,et al.Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis[J].Circulation,2001,103(20):2453-2460.
  • 8Buller HR,Agenelli G,Hull RD,et al.Antithrombotic therapy for venous thromboembolic disease:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 Suppl):S401-S428.Review.Erratum in:Chest.2005,127(1):416.
  • 9Lee AY,Levine MN,Baker RI,et al.Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer[J].N Engl J Med,2003,349(2):146-153.

二级参考文献22

  • 1Boehme MWJ, Raeth U, Galle PR, et al. Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol, 2000, 119:189-195.
  • 2Thomas GN, Tam LS, Tomlinson B, et al. Accelerated atherosclerosis in patients with systemic lupus erythematosus: a review of the causes and possible prevention. HMKJ, 2002, 8: 26-32.
  • 3Renaudineau Y, Dugue C, Dueymes M, et al. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev,2002, 1: 365-372.
  • 4Levy GA, Liu MF, Ding JW, et al. Molecular and functional analysis of the human prothrombinase gene (hfgl2) and its role in viral hepatitis. Am J Pathol, 2000, 156: 1217-1225.
  • 5Chan CW, Chan MW, Liu MF, et al. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J Immunol, 2002, 168:5170-5177.
  • 6Clark DA, Chaouat G, Arck PC, et al. Cytokine-dependent abortion in CBA × DBA/2 mice is mediated by the procoagulant fgl2prothrombinase (correction of prothombinase). J Immunol, 1998,160: 545-549.
  • 7Kim PO, Levy GA, Craig M, et al. Immune responses during smallintestine allograft rejection: correlation between procoagulant activity and histopathology. Transplant Proc, 1990, 23: 2477.
  • 8Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood, 2004,103: 3677-3683.
  • 9Brouwer JL, Bijl M, Veeger NJ, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004, 104:143-148.
  • 10Ginsberg JS, Demers C, Brill-Edwards P, et al. Increased thrombin generation and activity in patients with systemic lupus ery thematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood, 1993, 81: 2958-2963.

共引文献7

同被引文献34

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部